INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10587804
	Filing Date	2007-06-07
	First Named Inventor	Bouquin, T.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	0279us310

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code1	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code1	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030124555	A1	2003-07-03	Brasch, et al.	
	2	20040106118	A1	2004-06-03	Kolmar, et al.	
	3	20020086427	A1	2002-07-04	Leiden, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number3	Country Code2 i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	1162270	EP	A2	2001-12-12	SCRIPPS RESEARCH INST		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10587804
	Filing Date	2007-06-07
	First Named Inventor	Bouquin, T.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	0279us310

	2	1477808	EP	A1	2004-11-17	PROBIOGEN AG		☐
	3	2002034906	WO	A2	2002-05-02	GEORG AUGUST UNI GOETTINGEN		☐
	4	2003014361	WO	A1	2003-02-20	ALTANA PHARMA AG		☐
	5	2003099996	WO	A2	2003-12-04	Biogen, Inc.		☐
	6	2001044516	WO	A2	2001-06-21	Tularik Inc.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Abo T., et al. SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells 7(7):629-638, 2002.	☐
	2	Arner E.S.J., et al. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J. Mol. Biol. 292(5):1003-1016, 1999.	☐
	3	Bedwell D.M., et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nature Med. 3:1280-1284, 1997	☐
	4	Barton-Davis E.R., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104:375-381, 1999.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor	Bouquin, T.	
Art Unit		
Examiner Name		
Attorney Docket Number		0279us310

	5	Burke J F and Mogg, A E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 (17):6265-6272, 1985.	☐
	6	Chang C.C., et al. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17(8):793-797, 1999.	☐
	7	Gorman C.M., et al. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11 (21):7631-7648, 1983.	☐
	8	Howard M., et al. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 2:467-469, 1996.	☐
	9	Hunt L., et al. Fluorescent proteins in animal cells for process development:optimization of sodium butyrate treatment as an example. Biotechnol. Bioeng. 77(5):528-537, 2002.	☐
	10	Ikezawa, H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25 (4):409-417, 2002.	☐
	11	Kawagishi J., et al. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30 (2):224-232, 1995.	☐
	12	Kozak, M At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196(4):947-950, 1987.	☐
	13	Kurtzman A., et al. Advances in directed protein evolution by recursive genetic recombination applications to therapeutic proteins. Curr. Opin. Biotechnol. 12(4):361-370, 2001.	☐
	14	Manuvakhova M., et al. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6(7):1044-1055, 2000.	☐
	15	Millan, J.L. Molecular cloning and sequence analysis of human placental alkaline phosphatase. J. Biol. Chem. 261 (7):3112-3115, 1986.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10587804
	Filing Date		2007-06-07
	First Named Inventor	Bouquin, T.	
	Art Unit		
	Examiner Name		
	Attorney Docket Number		0279us310

	16	Pack P., et al Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol Biol 246 28-34, 1995.	☐
	17	Pack P., et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnol. 11 :1271-1277, 1993.	☐
	18	Pack P., and Plueckthun, A. Miniantibodies:use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31:1579-1584, 1992	☐
	19	Palmer E., et al. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 277 (5692):148-150, 1979.	☐
	20	Stansfield I., et al. The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae. EMBO J. 14:4365-4373, 1995.	☐
	21	Whalen R., et al. DNA shuffling and vaccines. Curr. Opin. Mol. Ther. 3 (1):31-36, 2001.	☐
	22	Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (6941):762-769, 2003.	☐
	23	Zhouravleva G., et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 14(16):4065-4072, 1995.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.